1. Home
  2. LKFN vs ANAB Comparison

LKFN vs ANAB Comparison

Compare LKFN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakeland Financial Corporation

LKFN

Lakeland Financial Corporation

HOLD

Current Price

$61.44

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

SELL

Current Price

$46.42

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LKFN
ANAB
Founded
1872
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
LKFN
ANAB
Price
$61.44
$46.42
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$66.00
★ $87.25
AVG Volume (30 Days)
225.3K
★ 435.1K
Earning Date
10-26-2026
11-17-2026
Dividend Yield
★ 3.31%
N/A
EPS Growth
N/A
★ 91.02
EPS
★ 3.31
N/A
Revenue
$985,000.00
★ $234,603,000.00
Revenue This Year
$6.70
N/A
Revenue Next Year
$5.38
$69.42
P/E Ratio
$19.00
★ N/A
Revenue Growth
N/A
★ 157.01
52 Week Low
$54.36
$30.27
52 Week High
$64.55
$73.30

Technical Indicators

Market Signals
Indicator
LKFN
ANAB
Relative Strength Index (RSI) 64.63 45.07
Support Level $58.59 $44.38
Resistance Level $64.14 $51.94
Average True Range (ATR) 1.43 2.37
MACD 0.46 0.20
Stochastic Oscillator 84.77 44.54

Price Performance

Historical Comparison
LKFN
ANAB

About LKFN Lakeland Financial Corporation

Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: